Vaccines-2013 - OMICS Group

Recommendations

Info

Min Shi Lee, J Vaccines Vaccin 2013, 4:5http://dx.doi.org/10.4172/2157-7560.S1.0163 rd International Conference onVaccines & VaccinationJuly 29-31, 2013 Embassy Suites Las Vegas, NV, USADevelopment of Vero cell-based influenza H5N1 vaccinesMin Shi LeeNational Health Research Institutes (NHRI), TaiwanCurrent egg-based influenza vaccine production technology is labor-intensive and lack of flexibility. Moreover, its capacitywould not be able to meet the demand during influenza pandemics. This was illustrated in the 2009 H1N1 pandemic whereonly 22% of expected doses were supplied within the first 6 months after the pandemic was declared. Therefore, cell-basedtechnology is becoming attractive for production of pandemic influenza vaccines. Two cell lines, MDCK and Vero cells arecurrently used for manufacturing human influenza vaccines. MDCK cells can only be used for manufacturing influenza vaccines.In contrast, Vero cells have been widely used for the production of human vaccines. The current WHO-recommended influenzaH5N1 clade-1 vaccine strain (NIBRG-14), a reassortant virus between A/Vietnam/1194/2004 (H5N1) virus and egg-adaptedhigh-growth A/PR/8/1934 virus, could grow efficiently in eggs and MDCK cells but not Vero cells. Therefore, we first adaptedthe egg-derived NIBRG-14 in Vero cells to become a Vero cell-adapted high-growth H5N1 vaccine virus (Vero-15), which couldreach high virus titer (>10 8 TCID50/ml) in Vero cells in multiple culture systems including T flasks, mirocarriers and TideCellcultures. Then, we established reverse genetics platform to generate high-growth reassortant H5N1 clade-2 viruses using theVero-15 virus as a master donor virus. In conclusion, the Vero-15 H5N1 vaccine virus has the commercial potential to become aseed virus for manufacturing H5N1 vaccines. In addition, the Vero-15 H5N1 vaccine virus could become a mater donor virus togenerate seed viruses for other influenza A subtypes.BiographyMin Shi Lee obtained his Ph.D. from Oxford University. He joined National Health Research Institutes as an Associate Investigator in 2005. Before that,he was Epidemiologist and scientist at MedImmune Vaccines, California, USA. He has won numerous awards, including National Innovation Award fromInstitute for Biotechnology and Medicine Industry and Outstanding Young Investigators Research Award from National Health Research Institute. Hisresearch interests include epidemiology of infectious diseases and development of influenza and enterovirus 71 vaccines. He has co-authored over 40original research articles and technology reports. Besides, he is a reviewer for several international journals.minshi@nhri.org.twJ Vaccines Vaccin 2013ISSN: 2157-7560, JVV an open access journalVaccines-2013July 29-31, 2013Volume 4 Issue 5Page 70
Gisela Gonzalez, J Vaccines Vaccin 2013, 4:5http://dx.doi.org/10.4172/2157-7560.S1.0163 rd International Conference onVaccines & VaccinationJuly 29-31, 2013 Embassy Suites Las Vegas, NV, USAInnovations in advanced cancer therapy: Therapeutic vaccines for chronic treatmentsGisela GonzalezCenter of Molecular Immunology, CubaThe impact of biotechnology in cancer therapy has been given by its possibilities for generation of novel biological products,characterized by:• high specificity• low toxicity (compatible with good quality of life)• possibility of being used chronically• possibility of being used in combinationsThe clinical course of a neoplastic disease goes through different clinical stages. If the disease is diagnosed in an earlystage, the patient receives attack treatment consisting in surgery, chemotherapy and / or radiotherapy. Some patients may havea complete or partial remission, but others may have an initial response followed by a disease relapse or simply progressionafter attack treatments. In this moment, patients receive first and/or second line treatments for advanced disease. Again, someresponses can be expected, but relapse can occur and then patients are considered in ¨terminal disease¨ stage, with progressivedisease after receiving all available onco-specific drugs. The term ¨terminal disease¨, doesn´t mean that the patient will dieimmediately, but that there are no other available therapies for treatment of the tumor, mainly because onco-specific drugstoxicity impairs patient conditions.The issue is to keep this advanced cancer patient´s alive, with a good quality of life, by applying non toxic treatments thatcan be given chronically. This is a change in the paradigm of cancer therapy that could mean to convert advanced cancer ina chronic disease which cannot be cured, but controlled for long periods of time with good quality of life for the patients.Therapeutic vaccines are novel tools for treating advanced cancer chronically. They are non toxic and its expected clinical effect isto increase patient´s survival with a good quality of life. Several cancer vaccines are in clinical testing. Here we are going to referto CIMAvaxEGF, an EGF based cancer vaccine, designed to provoke specific anti-EGF antibodies that ¨castrate¨ circulating EGFavoiding its further binding to the EGF receptor, and then, the unchain of proliferation mechanisms derived from this ligand/receptor binding. During its clinical development, has been demonstrated its efficacy in improving survival in advanced nonsmallcell lung cancer patients, as well as a high safety profile. The feasibility of giving long term treatments with CIMAvaxEGFhas also been demonstrated, opening the possibility of treating advanced lung cancer as a chronic disease.giselagm2007@yahoo.comJ Vaccines Vaccin 2013ISSN: 2157-7560, JVV an open access journalVaccines-2013July 29-31, 2013Volume 4 Issue 5Page 71
Page 1 and 2:
111 th OMICS Group ConferenceJuly 2
Page 3 and 4:
Medical SciencesISSNAddiction Resea
Page 5 and 6:
Impact Factors (IF) and Index Coper
Page 7 and 8:
111 th OMICS Group Conference3 rd I
Page 9 and 10:
Journal of Clinical & Cellular Immu
Page 11 and 12:
Page 13 and 14:
Page 15 and 16:
Clinical Microbiology-2013OMICS Gro
Page 17 and 18:
Immunology Summit-2013OMICS Group i
Page 19 and 20: Probiotics-2013OMICS Group is organ
Page 21 and 22: Virology-2013OMICS Group is organiz
Page 23 and 24: 111 th OMICS Group Conference3 rd I
Page 25 and 26: Because of heightened awareness of
Page 33 and 34: Ara Hovanessian, J Vaccines Vaccin
Page 35 and 36: Nikolai Petrovsky, J Vaccines Vacci
Page 39 and 40: Robert E. Sievers et al., J Vaccine
Page 41 and 42: Xiao-Qing Wei, J Vaccines Vaccin 20
Page 43 and 44: Campbell Bunce, J Vaccines Vaccin 2
Page 45 and 46: Hong Xin, J Vaccines Vaccin 2013, 4
Page 47 and 48: Diane Longo et al., J Vaccines Vacc
Page 49 and 50: Track 33: Novel Approaches in Desig
Page 51 and 52: Takashi Kei Kishimoto, J Vaccines V
Page 53 and 54: Benjamin Petsch, J Vaccines Vaccin
Page 55 and 56: A. Bennett Jenson et al., J Vaccine
Page 57 and 58: Milan Raska et al., J Vaccines Vacc
Page 59 and 60: Muhammad Ali A. Shah et al., J Vacc
Page 61 and 62: Track 44: Vaccines against Infectio
Page 63 and 64: Haval Shirwan, J Vaccines Vaccin 20
Page 65 and 66: Rainer Fischer, J Vaccines Vaccin 2
Page 67 and 68: Alwyn Rapose, J Vaccines Vaccin 201
Page 69: Saroj Basak, J Vaccines Vaccin 2013
Page 73 and 74: Young Research ForumSession ChairPe
Page 75 and 76: Humberto Hernandez et al., J Vaccin
Page 77 and 78: Nisha Nair et al., J Vaccines Vacci
Page 79 and 80: Leow Yee et al., J Vaccines Vaccin
Page 81 and 82: Kaissar Tabynov et al., J Vaccines
Page 83 and 84: Teena Mohan et al., J Vaccines Vacc
Page 85 and 86: Track 5 & 95: Manufacturing, Produc
Page 87 and 88: Graham Clarke, J Vaccines Vaccin 20
Page 89 and 90: Obradovic Zarema et al., J Vaccines
Page 91 and 92: Abdur Razzaque Sarker et al., J Vac
Page 93 and 94: Omer Qutaiba B. Al-lela et al., J V
Page 97 and 98: Regina Heidenreich et al., J Vaccin
Page 99 and 100: Leow Y et al., J Vaccines Vaccin 20
Page 101 and 102: Zafer Kurugol et al., J Vaccines Va
Page 103 and 104: Ates Kara et al., J Vaccines Vaccin
Page 105 and 106: Yurong Tan et al., J Vaccines Vacci
Page 107 and 108: Deryabin P.N. et al., J Vaccines Va
Page 109 and 110: Xiao-Yong Fan et al., J Vaccines Va
Page 111 and 112: Byung Chul Kim et al., J Vaccines V
Page 113 and 114: STS. Chitradevi et al., J Vaccines
Page 115 and 116: Yan Liang et al., J Vaccines Vaccin
Page 119 and 120: Afshineh Latifynia et al., J Vaccin
Page 121 and 122:
Hemanta Koley et al., J Vaccines Va
Page 123 and 124:
Aleksandar Masic et al., J Vaccines
Page 125 and 126:
Hassen Mamo, J Vaccines Vaccin 2013
Page 127 and 128:
Oladipo Aina et al., J Vaccines Vac
Page 129 and 130:
Aiswariya Chidambaram, J Vaccines V
Page 131 and 132:
Birhanu Hurisa et al., J Vaccines V
Page 133 and 134:
Ghaffarifar F et al., J Vaccines Va
Page 135 and 136:
Mathan Periasamy et al., J Vaccines
Page 137 and 138:
Rania Abdel Hay, J Vaccines Vaccin
Page 139 and 140:
Samuel Teshome, J Vaccines Vaccin 2
Page 141 and 142:
Page 143 and 144:
Birhanu Hurisa et al., J Vaccines V
Page 145 and 146:
Dhrubajyoti Nag, J Vaccines Vaccin
Page 147 and 148:
Belachew Etana et al., J Vaccines V
Page 149 and 150:
Fatemeh Ghaffarifar et al., J Vacci
Page 151 and 152:
Moustafa A.F. Abbas et al., J Vacci
Page 153 and 154:
Prerna Chaudhary, J Vaccines Vaccin
Page 155 and 156:
Sandeepkumar R. Chauhan et al., J V
Page 157 and 158:
Veronica Rainone et al., J Vaccines
Page 159 and 160:
Page 159
Page 161 and 162:
Previous111 th OMICS Group Conferen
Page 163 and 164:
PreviousWorld Congress and Expo onB
show all

Vaccines-2013 - OMICS Group

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?